Rachel L. Mintz

Rachel L. Mintz

Auto-generated profile, based on publicly available information

Rachel L. Mintz

Washington University School of Medicine Medical Scientist Training Program, Saint Louis, Missouri (R.M.)

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2019 in Nanoscale
Verified
Journal Article
Closed access
PDF file
Mingqiang LiMingqiang Li
Mingqiang Li
YLYeh-Hsing Lao
Yeh-Hsing Lao
RMRachel L. Mintz
Rachel L. Mintz
ZCZhuanggui Chen
Zhuanggui Chen
DSDan Shao
Dan Shao
KLKam W Leong
Kam W Leong
Breast cancer is the most common malignancy and also the second leading cause of cancer mortality in women globally. Strategies for early and precise detection of breast cancer cells are highly desired in breast cancer diagnosis and treatment. Here, we report on the efficient detection of HER2-positive (HER2+) breast cancer cells using an amplified signal scheme enabled by gold nanoclusters entrapped in mesoporous silica nanoparticles (MSNs). The utilization of MSNs as an excellent enzyme immobilization support and gold nanoclusters as an effective peroxidase mimic imparts high sensitivity to this detection platform. In addition, the inclusion of target-specific HER2 antibodies adds excellent selectivity. Determination of HER2+ cancer cells in breast cancer tissue demonstrates the potential application of this biosensor design in clinical diagnosis in particular, and bioanalysis in general.

15 August 2014 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
MSMalvika H. Solanki
Malvika H. Solanki
PCProdyot K. Chatterjee
Prodyot K. Chatterjee
MGMadhu Gupta
Madhu Gupta
XXXiangying Xue
Xiangying Xue
APAndrei Plagov
Andrei Plagov
CMChristine Noel Metz
Christine Noel Metz
Despite its success as a potent antineoplastic agent, ∼25% of patients receiving cisplatin experience acute kidney injury (AKI) and must discontinue therapy. Impaired magnesium homeostasis has been linked to cisplatin-mediated AKI, and because magnesium deficiency is widespread, we examined the effect of magnesium deficiency and replacement on cisplatin-induced AKI in physiologically relevant older female mice. Magnesium deficiency significantly increased cisplatin-associated weight loss and markers of renal damage (plasma blood urea nitrogen and creatinine), histological changes, inflammation, and renal cell apoptosis and modulated signaling pathways (e.g., ERK1/2, p53, and STAT3). Conversely, these damaging effects were reversed by magnesium. Magnesium deficiency alone significantly induced basal and cisplatin-mediated oxidative stress, whereas magnesium replacement attenuated these effects. Similar results were observed using cisplatin-treated LLC-PK1renal epithelial cells exposed to various magnesium concentrations. Magnesium deficiency significantly amplified renal platinum accumulation, whereas magnesium replacement blocked the augmented platinum accumulation after magnesium deficiency. Increased renal platinum accumulation during magnesium deficiency was accompanied by reduced renal efflux transporter expression, which was reversed by magnesium replacement. These findings demonstrate the role of magnesium in regulating cisplatin-induced AKI by enhancing oxidative stress and thus promoting cisplatin-mediated damage. Additional in vitro experiments using ovarian, breast, and lung cancer cell lines showed that magnesium supplementation did not compromise cisplatin's chemotherapeutic efficacy. Finally, because no consistently successful therapy to prevent or treat cisplatin-mediated AKI is available for humans, these results support developing more conservative magnesium replacement guidelines for reducing cisplatin-induced AKI in cancer patients at risk for magnesium deficiency.

1 August 2017 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
GKGopal Kumar
Gopal Kumar
MSMalvika H. Solanki
Malvika H. Solanki
XXXiangying Xue
Xiangying Xue
RMRachel Mintz
Rachel Mintz
SMSwati Madankumar
Swati Madankumar
CMChristine Noel Metz
Christine Noel Metz
Approximately 30% of all cancer patients treated with cisplatin, a widely used broad-spectrum chemotherapeutic agent, experience acute kidney injury (AKI). Almost all patients receiving cisplatin have magnesium (Mg) losses, which are proposed to aggravate AKI. Currently, there are no methods to successfully treat or prevent cisplatin-AKI. Whereas Mg supplementation has been shown to reduce AKI in experimental models and several small clinical trials, the effects of Mg status on tumor outcomes in immunocompetent tumor-bearing mice and humans have not been investigated. The purpose of this study was to further examine the effects of Mg deficiency (±Mg supplementation) on cisplatin-mediated AKI and tumor killing in immunocompetent mice bearing CT26 colon tumors. Using a model where cisplatin alone (20 mg/kg cumulative dose) produced minimal kidney injury, Mg deficiency significantly worsened cisplatin-mediated AKI, as determined by biochemical markers (blood urea nitrogen and plasma creatinine) and histological renal changes, as well as markers of renal oxidative stress, inflammation, and apoptosis. By contrast, Mg supplementation blocked cisplatin-induced kidney injury. Using LLC-PK1renal epithelial cells, we observed that Mg deficiency or inhibition of Mg uptake significantly enhanced cisplatin-induced cytotoxicity, whereas Mg supplementation protected against cytotoxicity. However, neither Mg deficiency nor inhibition of Mg uptake impaired cisplatin-mediated killing of CT26 tumor cells in vitro. Mg deficiency was associated with significantly larger CT26 tumors in BALB/c mice when compared with normal-fed control mice, and Mg deficiency significantly reduced cisplatin-mediated tumor killing in vivo. Finally, Mg supplementation did not compromise cisplatin’s anti-tumor efficacy in vivo.

24 October 2018 in Science and Engineering Ethics
Verified
Journal Article
Closed access
PDF file
RMRachel L. Mintz
Rachel L. Mintz
JLJohn D. Loike
John D. Loike
RFRuth L. Fischbach
Ruth L. Fischbach

9 November 2018 in Advanced Biosystems
Verified
Journal Article
Open access
PDF file
RMRachel L. Mintz
Rachel L. Mintz
MGMadeleine A. Gao
Madeleine A. Gao
KLKahmun Lo
Kahmun Lo
YLYeh‐Hsing Lao
Yeh‐Hsing Lao
Mingqiang LiMingqiang Li
Mingqiang Li
KLKam W. Leong
Kam W. Leong
Breast cancer is a highly heterogenous family of malignant neoplasms with significant interpatient variations. CRISPR technology offers a toolkit to diagnose, model, and treat the disease in a more precise manner. In article number 1800132, Kam W. Leong and co‐workers analyze the potential application of CRISPR technology in these three aspects and provide insights on developing a precision medicine‐based approach against breast cancer.

1 September 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
RCRobert M. Centor
Robert M. Centor
RMRachel Mintz
Rachel Mintz
LPLeah Pierson
Leah Pierson
In this episode of Annals On Call, Dr. Centor discusses the definition of professionalism in medicine with medical students Rachel Mintz and Leah Pierson.